IPO Date: Nov 29 to Dec 3 2024
Listing Date: Dec 6 2024
...
CRISIL Report). We also reported the highest compounded annual growth rate (“CAGR”) of 20.87% in terms of non-COVID revenues between Fiscals 2022 and 2024 among peers Agilus Diagnostics Limited, Dr. Lal Pathlabs Limited, Metropolis Healthcare Limited, Thyrocare Technologies Limited. (Source: CRISIL Report). We offer a one-stop integrated solution for pathology and radiology testing, and medical consultation services to our customers through our extensive operational network, consisting of our flagship central reference laboratory, 8 satellite laboratories (co-located with our diagnostic centers) and 194 customer touchpoints which include 48 diagnostic centres, and 146 sample collection centres (primarily franchised), as of March 31, 2024 across the states of West Bengal, Bihar, Assam, and Meghalaya. For details of our operational network, see “- Our Operational Network” on page 198. Our flagship central reference laboratory holds the College of American Pathologists accreditation. As of March 31, 2024, we are the only company providing diagnostic services and having a reference laboratory in East and North-East India to hold the College of American Pathologists accreditation. (Source: CRISIL Report). 3 of our laboratories hold National Accreditation Board for Testing and Calibration Laboratories (“NABL”) and 2 of our advanced diagnostic centres hold National Accreditation Board for Hospitals & Healthcare Providers (“NABH”) accreditations. As of March 31, 2024, 43 of our diagnostic centres also housed 120 polyclinic chambers hosting 750+ specialized doctors for patient convenience. During the Fiscal 2024, we conducted approximately 5.98 million tests serving approximately 1.14 million patients and derived 95.48% of our revenue from operations from our core geography, Kolkata and the rest of West Bengal. Read MoreK FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Posted on Dec 29th
Virtual Global Education informs about closure of trading window
Posted on Dec 29th
Rajya Sabha MP Sibal takes dig at govt over death of 33 BLOs during SIR exercise
Posted on Dec 29th
Currency futures for January expiry trade weaker with 47.03% increase in OI
Posted on Dec 24th
E to E Transportation Infrastructure coming with IPO to raise Rs 84 crore
The issue size of Suraksha Diagnostic Ltd. IPO is ₹564.17 - 592.37 crore.
The Suraksha Diagnostic Ltd. IPO opens for subscription on 2024-11-29 and closes on 2024-12-03.
The price range of Suraksha Diagnostic Ltd. IPO is ₹420.00 to ₹441.00.
The lot size of Suraksha Diagnostic Ltd. IPO is 34 shares.
The registrar of Suraksha Diagnostic Ltd. IPO is K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.).
This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.